MA29542B1 - Traitement des maladies hepatiques dans la pathogenese desquelles le fer joue un role - Google Patents

Traitement des maladies hepatiques dans la pathogenese desquelles le fer joue un role

Info

Publication number
MA29542B1
MA29542B1 MA30467A MA30467A MA29542B1 MA 29542 B1 MA29542 B1 MA 29542B1 MA 30467 A MA30467 A MA 30467A MA 30467 A MA30467 A MA 30467A MA 29542 B1 MA29542 B1 MA 29542B1
Authority
MA
Morocco
Prior art keywords
treatment
pathogenesis
role
hepatic diseases
iron plays
Prior art date
Application number
MA30467A
Other languages
English (en)
Inventor
Daniele Alberti
Peter Marks
Hanspeter Nick
Lisa Grace Rojkjaer
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA29542B1 publication Critical patent/MA29542B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'INVENTION CONCERNE L'UTILISATION D'ACIDE 4-[3,5-BIS-(2-HYDROXYPHÉNYL)-[1,2,4]-TRIAZOL-1-YL]BENZOÏQUE (APPELÉ ICI 'COMPOSÉ I') DANS LA FABRICATION DE COMPOSITIONS PHARMACEUTIQUES UTILES DANS LE TRAITEMENT DE MALADIES HÉPATIQUES HUMAINES DANS LA PATHOGENÈSE DESQUELLES LE FER JOUE UN RÔLE, NOTAMMENT DES MALADIES VIRALES, TELLES QUE L'HÉPATITE C CHRONIQUE, FACULTATIVEMENT ASSOCIÉES À DES AGENTS ANTIVIRAUX, ET DANS LE TRAITEMENT DE MALADIES NON VIRALES, TELLES QUE LA STÉATOHÉPATITE NON ALCOOLIQUE ET LA STÉATOSE HÉPATIQUE NON ALCOOLIQUE.
MA30467A 2005-05-31 2007-12-10 Traitement des maladies hepatiques dans la pathogenese desquelles le fer joue un role MA29542B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US68584805P 2005-05-31 2005-05-31
US69280805P 2005-06-22 2005-06-22
US74678606P 2006-05-09 2006-05-09

Publications (1)

Publication Number Publication Date
MA29542B1 true MA29542B1 (fr) 2008-06-02

Family

ID=37106984

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30467A MA29542B1 (fr) 2005-05-31 2007-12-10 Traitement des maladies hepatiques dans la pathogenese desquelles le fer joue un role

Country Status (16)

Country Link
US (3) US20080199428A1 (fr)
EP (1) EP1893198A2 (fr)
JP (2) JP2008542380A (fr)
KR (2) KR101174966B1 (fr)
AU (1) AU2006252718B2 (fr)
BR (1) BRPI0610873A2 (fr)
CA (1) CA2608709A1 (fr)
CR (1) CR9454A (fr)
EA (1) EA014772B1 (fr)
IL (1) IL187000A0 (fr)
MA (1) MA29542B1 (fr)
MX (1) MX2007015085A (fr)
NO (1) NO20076595L (fr)
SM (1) SMAP200700061A (fr)
TN (1) TNSN07447A1 (fr)
WO (1) WO2006130532A2 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PY0111577A (es) 2000-05-23 2017-01-02 Idenix Cayman Ltd Métodos y composiciones para el tratamiento del virus de la hepatitis c
AP2006003708A0 (en) 2000-05-26 2006-08-31 Idenix Cayman Ltd Methods and compositions for treating flavivirusesand pestiviruses
CN1678326A (zh) 2002-06-28 2005-10-05 埃迪尼克斯(开曼)有限公司 用于治疗黄病毒感染的2'－c－甲基－3'－o－l－缬氨酸酯核糖呋喃基胞苷
CN101172993A (zh) 2002-06-28 2008-05-07 埃迪尼克斯(开曼)有限公司 用于治疗黄病毒感染的2′－c－甲基－3′－o－l－缬氨酸酯核糖呋喃基胞苷
RU2005118421A (ru) 2002-11-15 2006-01-20 Айденикс (Кайман) Лимитед (Ky) 2'-разветвленные нуклеозиды и мутация flaviviridae
PL377287A1 (pl) 2002-12-12 2006-01-23 Idenix (Cayman) Limited Sposób wytwarzania 2'-rozgałęzionych nukleozydów
EP1917037A2 (fr) * 2005-08-15 2008-05-07 F.Hoffmann-La Roche Ag Peg-ifn alpha et ribavirine permettant le traitement du virus hbv
CA2670313C (fr) * 2006-11-29 2013-02-12 Novartis Ag Formes polymorphes de deferasirox (icl670a)
EP1927591A1 (fr) * 2006-11-29 2008-06-04 Novartis AG Formes polymorphes de deferasirox (ICL670)
US9370528B2 (en) * 2011-03-02 2016-06-21 Volant Holdings Gmbh Compositions, methods of treatment and diagnostics for treatment of hepatic steatosis alone or in combination with a hepatitis C virus infection
CN104023726A (zh) 2011-10-21 2014-09-03 艾伯维公司 用于治疗hcv的一种或多种daa的联合治疗(例如，与abt-072或abt-333)
CA2811203C (fr) 2011-10-21 2015-05-05 Abbvie Inc. Methodes de traitement du vhc
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
KR102051031B1 (ko) * 2011-10-28 2019-12-02 루메나 파마수티컬즈, 인코포레이티드 고담혈증 및 담즙 정체성 간 질환 치료용 담즙산 재순환 억제제
EP3922246A1 (fr) * 2014-03-21 2021-12-15 Tobira Therapeutics, Inc. Cénicriviroc pour le traitement de la fibrose
JP7129703B2 (ja) 2016-04-28 2022-09-02 エモリー ユニバーシティー アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用
GB202005054D0 (en) 2020-04-06 2020-05-20 Nemysis Ltd Carboxylate Ligand Modified Ferric Iron Hydroxide Compositions for Use in the Treatment or Prevention of Iron Deficiency Associated with Liver Diseases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW533205B (en) * 1996-06-25 2003-05-21 Novartis Ag Substituted 3,5-diphenyl-l,2,4-triazoles and their pharmaceutical composition
JP4125011B2 (ja) * 2002-01-22 2008-07-23 株式会社 伊藤園 過剰鉄起因肝障害予防・治療剤及び過剰鉄起因肝障害予防・治療飲食物

Also Published As

Publication number Publication date
JP2013082726A (ja) 2013-05-09
US20100098662A1 (en) 2010-04-22
CA2608709A1 (fr) 2006-12-07
IL187000A0 (en) 2008-02-09
AU2006252718B2 (en) 2010-04-15
AU2006252718A1 (en) 2006-12-07
WO2006130532A3 (fr) 2007-11-22
EP1893198A2 (fr) 2008-03-05
JP5869469B2 (ja) 2016-02-24
CR9454A (es) 2008-04-16
EA200702384A1 (ru) 2008-06-30
TNSN07447A1 (en) 2009-03-17
US20130109730A1 (en) 2013-05-02
BRPI0610873A2 (pt) 2010-08-03
SMAP200700061A (it) 2007-12-28
US20080199428A1 (en) 2008-08-21
JP2008542380A (ja) 2008-11-27
NO20076595L (no) 2007-12-20
WO2006130532A2 (fr) 2006-12-07
KR20100018057A (ko) 2010-02-16
KR101174966B1 (ko) 2012-08-17
MX2007015085A (es) 2008-01-17
KR20080003933A (ko) 2008-01-08
EA014772B1 (ru) 2011-02-28

Similar Documents

Publication Publication Date Title
NO20076595L (no) Behandling av leversykdommer hvor jern spiller en rolle i patogenesen
BRPI0415121A (pt) material particulado, forma de dosagem sólida, método para fabricar a mesma, e, uso de um material particulado ou de uma forma de dosagem sólida
TNSN08505A1 (fr) Compositions pharmaceutiques stabilisees comprenant de la fesoterodine
MA28437B1 (fr) Composes et leurs procedes d'utilisation
MA32070B1 (fr) Dérivés hétérocycliques réunis par fusion et procédés d'utilisation associés
EA200702198A1 (ru) Фармацевтические составы
MA34013B1 (fr) Inhibiteurs du virus de l'hépatite c
ECSP066959A (es) Compuestos macrociclicos como inhibidores de la replicación viral
CY1111755T1 (el) Μεθοδοι και συνθεσεις για μειωση ποσοτητων ιικου γονιδιωματος hcv σε ενα κυτταρο στοχο
DK1485080T3 (da) Anvendelse af adapalen til behandling af dermatologiske sygdomme
BR0317572A (pt) Benzoxazinas e seus derivados como inibidores de pi3ks
BRPI0508579A (pt) composto, composição farmacêutica, e, uso de um composto
CU20090112A6 (es) Compuestos macrocíclicos como inhibidores de la replicación viral
EP2005962A4 (fr) Agent therapeutique pour affection abdominale inflammatoire
NO20076405L (no) Anvendelse av 24-nor-UDCA
BR9914419A (pt) Terapia para melhoria da percepção
ATE414531T1 (de) Verbesserte antimikrobielle peroxidase- zusammensetzungen
EP1930002A4 (fr) Utilisation d'ester d'acide hydroxybenzoïque et d'analogues pour la fabrication d'un médicament pour la prévention et le traitement d'infection virale
MA33563B1 (fr) 5-(3,4-dichloro-phényl)-n-(2-hydroxy-cyclohexyl)-6-(2,2,2-trifluoro-éthoxy)-nicotinamide et ses sels utilisés comme agents augmentant le cholestérol hdl
PE20001496A1 (es) Formulacion de liberacion controlada para el tratamiento de epoc
WO2006138088A3 (fr) Compositions et procedes d'utilisation desdites compositions
FR3050112B1 (fr) Utilisation de l'acide fenofibrique dans le traitement des maladies hepatiques
WO2004037853A3 (fr) Quinolones ayant une activité anti-vih
RU2007138263A (ru) Противовоспалительные соединения
BRPI0608287A2 (pt) agente endoparasiticida